ClinicalTrials.gg
CompletedNCT06811246Updated Feb 6, 2025

A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)

A Phase 1 interventional study of Islatravir (ISL) and Lamivudine (3TC) in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 4 months ago, and no results have been posted to the registry.
  • Registered 11 months after the study started (first participant enrolled Feb 2024, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to learn what happens to the medication islatravir (ISL), in a healthy person's body over time--called a pharmacokinetic (PK) study. Researchers want to compare the amount of islatravir in the blood when it is taken alone as a single dose and when it is taken with multiple doses of another medication called lamivudine (3TC).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health before randomization
  • Has a (BMI) ≥18 and ≤32 kg/m\^2

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Is a smoker and/or has used nicotine or nicotine-containing products (for example, nicotine patch and electronic cigarette) within 3 months prior to entering the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    ISL and 3TC

    During period 1, participants receive a single dose of islatravir (ISL). During Period 2, participants receive multiple once-daily doses of lamivudine (3TC) for 27 days, and a single dose of ISL co-administered with 3TC on day 6.

    Drug: Islatravir (ISL) · Drug: Lamivudine (3TC)

Interventions

  • Oral administration of a single dose in period 1 and period 2

    Also known as: MK-8591, ISL

  • Oral administration of multiple daily doses for 27 days

    Also known as: 3TC

06

What researchers measure

Primary outcomes

  1. Peripheral blood mononuclear cell (PBMC) Concentration at 168 hours (C168) of islatravir-triphosphate (ISL-TP )

    Blood samples will be collected to determine the C168 of ISL-TP

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  2. PBMC Concentration at 24 Hours (C24) of ISL-TP

    Blood samples will be collected to determine the C24 of ISL-TP

    Time frame: Predose and at designated timepoints up to 24 hours post dose

  3. PBMC Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of ISL-TP

    Blood samples will be collected to determine the AUC0-inf of ISL-TP

    Time frame: Predose and at designated timepoints up to 840 hours post dose

  4. PBMC Area Under the Concentration-time Curve to Time of Last Measurable Concentration (AUClast) of ISL-TP

    Blood samples will be collected to determine the AUClast of ISL-TP

    Time frame: Predose and at designated time points up to 840 hours post dose

  5. PBMC Maximum Concentration (Cmax) of ISL-TP

    Blood samples will be collected to determine the Cmax of ISL-TP

    Time frame: Predose and at designated time points up to 840 hours post dose

  6. PBMC Time to Maximum Concentration (Tmax) of ISL-TP

    Blood samples will be collected to determine the Tmax of ISL-TP

    Time frame: Predose and at designated time points up to 840 hours post dose

  7. PBMC Apparent Terminal Half-life (t1/2) of ISL-TP

    Blood samples will be collected to determine the t1/2 of ISL-TP

    Time frame: Predose and at designated timepoints up to 840 hours post dose

Secondary outcomes

  1. Plasma C168 of ISL

    Blood samples will be collected to determine the C168 of ISL

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  2. Plasma Concentration at 24 Hours (C24) of ISL

    Blood samples will be collected to determine the C24 of ISL

    Time frame: Predose and at designated timepoints up to 24 hours post dose

  3. Plasma AUC0-inf of ISL

    Blood samples will be collected to determine the AUC0-inf of ISL

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  4. Plasma AUClast of ISL

    Blood samples will be collected to determine the AUClast of ISL

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  5. Plasma Cmax of ISL

    Blood samples will be collected to determine the Cmax of ISL

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  6. Plasma Tmax of ISL

    Blood samples will be collected to determine the Tmax of ISL-TP

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  7. Plasma t1/2 of ISL

    Blood samples will be collected to determine the t1/2 of ISL

    Time frame: Predose and at designated timepoints up to 168 hours post dose

  8. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 16 weeks

  9. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported

    Time frame: Up to approximately 10 weeks

07

Study locations

1 site
  • Celerion (Site 0001)
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jul 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2025
First posted
Feb 6, 2025
StartActual
Feb 7, 2024
Primary completionActual
Jul 14, 2024
CompletionActual
Jul 14, 2024
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06811246
Responsible party
Sponsor
First posted
Feb 6, 2025
Start date
Feb 7, 2024
Primary completion
Jul 14, 2024
Completion
Jul 14, 2024
Last update
Feb 6, 2025

Study contacts

Medical DIrector
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Islatravir · Lamivudine

Start the discussion